Vosoritide therapy in Brazil: Consensus on the Diagnosis, Monitoring, and Management of Achondroplasia

FGFR3

Vosoritide, the first precision pharmacological therapy for achondroplasia, in children with open growth plates

Achondroplasia is the most common non-lethal disproportionate skeletal dysplasia, with lifelong medical, functional and psychosocial complications. Vosoritide significantly improves annualized growth velocity and body proportionality in children with open growth plates, and is the only disease-modifying therapy approved by the Brazilian regulatory agency in this indication. A multidisciplinary Guideline Development Group of specialists from several regions of Brazil and patient representatives formulated recommendations through literature review, expert discussion and a two-round Delphi survey. The consensus covers pre-treatment evaluation, initiation criteria, dose selection, education and consent, monitoring, dose adjustment, discontinuation and post-treatment follow-up, with key principles being genetic confirmation of the diagnosis, early initiation in eligible patients and lifelong multidisciplinary care.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The value of this text is that it goes to the end of the chain: whom to treat, at what dose, what to monitor, when to stop, where trials stop at growth velocity. Genetic confirmation of the diagnosis before prescribing is restated as a prerequisite, which directly concerns genetics clinics. This is an expert consensus contextualized to the Brazilian healthcare system, with no explicit literature search method or evidence grading: transposition should be cautious.

Analysis by Dr Thibaut Benquey